| (Values in U.S. Thousands) | Dec, 2015 | Sep, 2015 | Jun, 2015 | Mar, 2015 | Dec, 2014 |
| Sales | -9,999,000 | 24,730 | 26,370 | 20,420 | 26,030 |
| Sales Growth | -40,532.67% | -6.22% | +29.14% | -21.55% | +18.37% |
| Net Income | -9,999,000 | -11,700 | -8,410 | -7,270 | -2,290 |
| Net Income Growth | -85,361.55% | -39.12% | -15.68% | -217.47% | -179.27% |
Dyax Corp (DYAX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Dyax Corp is a biopharmaceutical company that has developed and patented a method that is used to identify a broad range of compounds with potential for the treatment and diagnosis of diseases. The company is also using this method to identify compounds that could be used in purifying andmanufacturing biopharmaceuticals and other chemicals. The company's phage display technology to rapidly and cost-effectively determine the potential medical uses of newly discovered proteins and genes and subsequently discover biopharmaceutical product candidates.
Fiscal Year End Date: 12/31